Anti-CD279 (PD-1) Antibody Drug Pipeline Research Report 2024: Insights on 40+ Companies Featuring GlaxoSmithKline, Innovent Biologics, BeiGene, and Shanghai Junshi Biosciences
April 11, 2024 09:15 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Anti-CD279 (PD-1)...
Nasopharyngeal Cancer Market Set for Exceptional Growth: Forecast Analysis 2024-2034 with Focus on Chemotherapy and Asia-Pacific Region
January 29, 2024 05:03 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Nasopharyngeal Cancer Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.In the recent...
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
December 19, 2022 08:00 ET
|
Immix Biopharma, Inc.
Tislelizumab supplied by BeiGene as part of ImmixBio’s Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid TumorsIMX-110 + Tislelizumab...
I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential
February 17, 2021 08:38 ET
|
Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering. This...
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China
June 19, 2020 00:27 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
April 20, 2020 16:05 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
April 13, 2020 16:05 ET
|
BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
April 10, 2020 18:00 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
January 21, 2020 07:00 ET
|
BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies
December 27, 2019 22:30 ET
|
BeiGene, LTD.
Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophages BEIJING, China and...